CA-170

• UNSPSC Description:

  CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes[1][2].

• Target Antigen:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/L-Threonine,_N-[[[_1S_-3-amino-1-[3-[_1R_-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]amino]carbonyl]-.html

• Purity:

  99.39

• Solubility:

  DMSO : 28.5 mg/mL (ultrasonic;warming)

• Smiles:

  C[C@@H](O)[C@@H](C(O)=O)NC(N[C@H](C1=NC([C@@H](N)CO)=NO1)CC(N)=O)=O

• Molecular Weight:

  360.32

• References & Citations:

  [1]Pottayil Govindan Nair Sasikumar, et al. 1,2,4-oxadiazole derivatives as immunomodulators. WO2015033299A1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  1673534-76-3